Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGD3 is an oral nutritional supplement developed by Pharmed. It is formulated as a combination of highly bioavailable magnesium glycine complex (magnesium glycinate) and vitamin D3 (cholecalciferol). Magnesium acts as an essential cofactor in the enzymatic activation of vitamin D3, while vitamin D3 enhances calcium absorption and bone mineralization. Together, they work synergistically to support bone, muscle, metabolic, and neurological health. MGD3 is primarily used to treat or prevent magnesium and vitamin D3 deficiencies, alleviate muscle cramps, and support musculoskeletal and metabolic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MGD3.